Sanjeev Thohan

Dr. Sanjeev Thohan is Vice President for Nonclinical Development at Kinnate Biopharma. He holds MS and PhD degrees in Pharmacology and Toxicology from the University of Arizona and University of Maryland with concentrations in interspecies drug metabolism mechanisms, bioactivation, and systems toxicology. He has held positions in increasing responsibility covering disciplines of ADME, DMPK and TOX areas of preclinical translational research with small and large organizations for both small and large molecule modalities (Walter Reed Army Institute for Research, Covance, AstraZeneca, ViroPharma, Exelixis, Novartis and Xeris). Sanjeev has extensive experience in Oncology drug discovery, biomarker identification, companion diagnostic identification and drug development from his time at Novartis (NIBR) and Exelixis with many clinical successes. He continues to be a contributing member of several national/international scientific societies. He serves as a subject matter expert in the drug and device arenas as well as allied technology applications for medicine. Sanjeev is an active mentor with the Centers for advancing Innovation (NIH collaboration) as well as a Scientific Advisory Board member for Cogentis Therapeutics (ALZ), Phoenix Molecular Designs (ONC) and RanTran (ALS).